AbbVie (NYSE:ABBV) Trading Down 1.1% - Time to Sell?

Key Points

• FDA Complete Response Letter for trenibotulinumtoxinE citing manufacturing/process issues has delayed potential commercialization and prompted near‑term selling pressure on AbbVie shares.
• Offsetting the setback, AbbVie is investing in growth with a $1.4 billion drug‑manufacturing campus in Durham and a licensing deal for pain medicines, while analysts (e.g., Canaccord initiating a Buy with a $262 target) and a MarketBeat consensus target around $253 portray the stock as a pullback/dividend opportunity.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price dropped 1.1% during mid-day trading on Friday . The stock traded as low as $197.14 and last traded at $198.7110. Approximately 7,602,917 shares were traded during trading, an increase of 6% from the average daily volume of 7,171,604 shares. The stock had previously closed at $200.95.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a planned $1.4 billion advanced drug‑manufacturing campus in Durham, NC — a large, multi‑year capital commitment that strengthens capacity, creates jobs and supports future product scaling. AbbVie selects Durham County for new $1.4B drug manufacturing facility
• Positive Sentiment: Canaccord initiated coverage with a Buy and a $262 price target (noted in recent writeups), reinforcing upside expectations from analysts after recent pullback. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Positive Sentiment: AbbVie expanded its R&D/commercial footprint with an exclusive licensing agreement for pain medicines (Haisco), which could broaden future revenue streams if development and commercialization succeed. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Neutral Sentiment: Wall Street previews and models for Q1 (sales/earnings and key metric estimates) are circulating ahead of AbbVie’s April 29 report — analysts expect revenue and EPS in line with recent guidance but emphasize pipeline catalysts as primary drivers of re-rating. Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics
• Neutral Sentiment: Recent coverage pieces label ABBV a high‑quality dividend/pullback opportunity given cash flow and payout history — supportive for income investors but not an immediate catalyst. 10 Dividend Growth Stocks: April 2025
• Negative Sentiment: FDA issued a Complete Response Letter for trenibotulinumtoxinE (TrenibotE) tied to manufacturing/process concerns; AbbVie says no new clinical studies were requested and it will respond, but the CRL delays potential commercial timing and spurred selling. AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
• Negative Sentiment: Major outlets report the FDA declined approval of AbbVie’s wrinkle/neurotoxin application because of manufacturing concerns — a near‑term setback for a high‑visibility franchise and a reminder of regulatory/manufacturing execution risk. US FDA declines to approve AbbVie's wrinkle treatment

Analyst Ratings Changes

ABBV has been the subject of several research analyst reports. UBS Group lowered their price target on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a report on Thursday, February 5th. Cantor Fitzgerald lowered their price target on shares of AbbVie from $250.00 to $240.00 and set an "overweight" rating for the company in a report on Wednesday, April 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Canaccord Genuity Group initiated coverage on shares of AbbVie in a report on Monday. They set a "buy" rating and a $262.00 price target for the company. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.19.

AbbVie Price Performance

The firm has a market capitalization of $351.35 billion, a price-to-earnings ratio of 84.20, a P/E/G ratio of 0.72 and a beta of 0.38. The stock has a fifty day moving average of $217.33 and a two-hundred day moving average of $222.62.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.22 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

Institutional Trading of AbbVie

A number of large investors have recently bought and sold shares of ABBV. Chelsea Counsel Co. acquired a new stake in AbbVie during the 3rd quarter worth about $26,000. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie during the 4th quarter worth about $28,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth about $29,000. Imprint Wealth LLC grew its holdings in AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the 3rd quarter worth about $31,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.